Mr. Rosen was appointed interim Chief Executive Officer effective April 1, 2015. Mr. Rosen is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), ALCOBRA, LTD (NASDAQ: ADHD), where he has served as Chairman since 2014, ALDEA Pharmaceuticals, Inc., Entrega, Inc., Kala Pharmaceuticals, Inc., where he has served as Chairman since 2014 and PaxVax, Inc., where he has served as Chairman since 2011. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to joining Gilead, Mr. Rosen was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co. Previously he was a member of the BODs of CNS Therapeutics, Inc., CoTherix, Inc., NTF Therapeutics, Inc., Pearl Therapeutics, Inc., where he served as interim President and CEO from June 2010 to March 2011, and Pharsight Corporation. Mr. Rosen received an MBA from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has an MS in Chemical Engineering from MIT and he graduated with distinction from Stanford University with a BS in Chemical Engineering. Mr Rosen was elected to the National Academy of Engineering in 2005.
Dr. Palmer has served as our director and Chief Medical Officer since she co-founded the company in July 2005. Dr. Palmer has been on faculty at the University of California, San Francisco since 1996 and is currently a Clinical Professor of Anesthesia and Perioperative Care. Dr. Palmer was Director of UCSF PainCARE-Center for Advanced Research and Education from 2005 to 2009, and was Medical Director of the UCSF Pain Management Center from 1999 to 2005. Dr. Palmer has been a consultant of Omeros Corporation, a biopharmaceutical company, since she co-founded that company in 1994. Dr. Palmer holds an M.D. from Stanford University and a Ph.D. from the Stanford Department of Neuroscience.
Mr. Hamel has served as our Chief Development Officer since September 2006. From 1986 until September 2006, Mr. Hamel served as Product Development Manager, Director Project Management, Executive Director Oral Product Development, and Vice President Oral Products Development at ALZA Corporation. From 1977 until 1985, Mr. Hamel held a number of positions at ALZA Corporation, including Senior Chemist, Research Scientist, and Senior Research Fellow. Mr. Hamel holds a B.S. in Biology from the University of Michigan.
Mr. Dasu has served as our Chief Engineering Office since September 2007. From December 2005 until September 2007, Mr. Dasu served as Vice President of Medical Device Engineering at Anesiva, a biopharmaceutical company. From March 2002 until December 2005, Mr. Dasu served as Vice President for Manufacturing and Device Development at AlgoRx Pharmaceuticals, Inc., an emerging pain management company, which merged with Corgentech Inc. in December 2005. From January 2000 until March 2002, Mr. Dasu served as Vice President of Manufacturing and Process Development at PowderJect Pharmaceuticals, a vaccine, drug and diagnostics delivery company that was acquired by Chiron Corporation in 2003 and later acquired by Novartis AG, a global healthcare and pharmaceutical company in 2006. Previously, Mr. Dasu served in various capacities in process development at Metrika, Inc., a company focused on the manufacture and marketing of disposable diabetes monitoring products that was acquired by Bayer HealthCare, LLC in 2006 and at Cygnus, Inc., a drug delivery and specialty pharmaceuticals company. Mr. Dasu holds a B.E. in Chemical Engineering from the University of Mangalore, India and M.S. in Chemical Engineering from the University of Tulsa.
Mr. Morris joined as Chief Financial Officer in 2014. Previously, Mr. Morris served as a Chief Financial Officer, Senior Vice President Finance and Global Corporate Development of VIVUS, Inc. from November 2004 to December 2013. At VIVUS Mr. Morris oversaw finance, corporate development, IT, human resources, legal, and investor relations functions. Prior to VIVUS, Mr. Morris was CFO, Senior Vice President Finance, Manufacturing and Administration from September 2001 to November 2004, and was a member of the Office of the President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development, acquisition, and marketing of pharmaceutical products. Mr. Morris graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.
Ms. Gaumer has over twenty years of US and European regulatory affairs and quality experience, covering both drug and drug-device product candidates. Prior to joining AcelRx she spent three years at Zosano Pharmaceuticals, Inc., a company spun out of Johnson & Johnson (J&J), where she was Vice President, Regulatory Affairs and Quality Assurance, focused on establishing and leading their regulatory, quality assurance and quality control organizations. Prior to Zosano, Kim held positions of increasing regulatory responsibility at ALZA Corporation, a J&J company, most recently serving as Senior Director, Regulatory Affairs. At ALZA, Ms. Gaumer provided regulatory supervision for several development programs through Phase 3b including both NDA and MAA filing experiences. She holds a Bachelor of Arts Degree in Human Biology from Stanford University.
Mr. Evashenk has over 25 years of pharmaceutical and device development experience with a focus on project management and clinical operations. Prior to joining AcelRx, Mark was Director of Clinical Operations at ALZA Corporation, a Johnson & Johnson Company. Throughout his career he managed 2 NDA filings and helped lead a clinical operations team for 2 additional NDA submissions, all of which resulted in commercial launches. He has managed clinical operations teams for well over 100 phase I studies, including over 10 first in man, and numerous phase II, III and IIIB studies. Mark has managed studies in the US, Canada, Western Europe and Eastern Europe, India and Australia. Mark holds his BS degree in Environmental Toxicology from UC Davis.
Jane Wright-Mitchell has served as our Chief Legal Officer since July 2014. Prior to joining the Company, from January 2012 to June 2014, Ms. Wright-Mitchell served as Associate General Counsel at Mesoblast, Inc., a regenerative medicine company utilizing adult mesenchymal precursor cells and culture expanded mesenchymal stem cell platform technologies to develop novel therapies for cardiovascular, orthopedic and immunologic indications. Prior to joining Mesoblast, Ms. Wright-Mitchell held the position of Assistant General Counsel at Purdue Pharma and Associate General Counsel at NeurogesX, Inc., respectively. Ms Wright-Mitchell received her J.D. from Chicago-Kent College of Law, PharmD from the University of Illinois, Chicago and B.S. in Biological Sciences from Clemson University. She is a registered pharmacist (Illinois) and registered to practice before the US Patent and Trademark Office.